These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9595974)

  • 41. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
    Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
    Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials.
    Truyen L; Barkhof F; Tas M; Van Walderveen MA; Frequin ST; Hommes OR; Nauta JJ; Polman CH; Valk J
    Mult Scler; 1997 Jan; 2(6):283-90. PubMed ID: 9065919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: correlations with changes of T2 and magnetization transfer lesion loads.
    Filippi M; Rocca MA; Horsfield MA; Comi G
    J Neurol Sci; 1998 Jun; 158(2):203-8. PubMed ID: 9702692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
    Humle Jorgensen S; Sorensen PS
    J Neurol Sci; 2005 Jun; 233(1-2):61-5. PubMed ID: 15949496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.
    Léger JM; Chassande B; Musset L; Meininger V; Bouche P; Baumann N
    Brain; 2001 Jan; 124(Pt 1):145-53. PubMed ID: 11133794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Comi G; Pulizzi A; Rovaris M; Abramsky O; Arbizu T; Boiko A; Gold R; Havrdova E; Komoly S; Selmaj K; Sharrack B; Filippi M;
    Lancet; 2008 Jun; 371(9630):2085-92. PubMed ID: 18572078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis.
    Filippi M; Rocca MA; Pagani E; Iannucci G; Sormani MP; Fazekas F; Ropele S; Hommes OR; Comi G
    Arch Neurol; 2004 Sep; 61(9):1409-12. PubMed ID: 15364687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined immunoglobulin and azathioprine in multiple sclerosis.
    Kalanie H; Tabatabai SS
    Eur Neurol; 1998; 39(3):178-81. PubMed ID: 9605396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.
    Thorpe JW; Kidd D; Moseley IF; Kenndall BE; Thompson AJ; MacManus DG; McDonald WI; Miller DH
    Neurology; 1996 Feb; 46(2):373-8. PubMed ID: 8614497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.
    Koudriavtseva T; Thompson AJ; Fiorelli M; Gasperini C; Bastianello S; Bozzao A; Paolillo A; Pisani A; Galgani S; Pozzilli C
    J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):285-7. PubMed ID: 9069488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
    Kappos L; Arnold DL; Bar-Or A; Camm J; Derfuss T; Kieseier BC; Sprenger T; Greenough K; Ni P; Harada T
    Lancet Neurol; 2016 Oct; 15(11):1148-59. PubMed ID: 27543447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.